论文部分内容阅读
目的探讨二甲双胍对合并2型糖尿病(T2DM)的中晚期宫颈癌患者放化疗疗效的影响。方法 43例ⅡB~ⅢB期宫颈癌合并T2DM的患者随机分为两组,分别采用二甲双胍联合同步放化疗(试验组,23例)和口服其他降糖药联合相同同步放化疗(对照组,20例)。比较两组近期、远期疗效和不良反应。结果试验组客观缓解率高于对照组(73.9%vs.65.0%),但差异无统计学意义(P>0.05)。试验组和对照组中位疾病无进展生存期和中位总生存期比较差异无统计学意义(25.1个月vs.23.5个月和25.6个月vs.25.8个月)(P>0.05)。试验组发生放射性膀胱炎比例高于对照组(P<0.05),而两组间发生胃肠道反应、骨髓抑制和放射性直肠炎的比例差异无统计学意义(P>0.05)。结论二甲双胍可能对合并T2DM的中晚期宫颈癌患者放化疗具有增敏作用。
Objective To investigate the effect of metformin on the efficacy of radiotherapy and chemotherapy in advanced cervical cancer patients with type 2 diabetes mellitus (T2DM). Methods Forty-three patients with stage ⅡB-ⅢB cervical cancer complicated with T2DM were randomly divided into two groups. Metformin combined with concurrent chemoradiotherapy (experimental group, 23 cases) and oral hypoglycemic agents combined with the same concurrent chemoradiotherapy (control group, 20 cases ). Compare the two groups of short-term, long-term efficacy and adverse reactions. Results The objective remission rate of the experimental group was higher than that of the control group (73.9% vs 65.0%), but the difference was not statistically significant (P> 0.05). There was no significant difference in median progression-free survival and median overall survival between the experimental group and the control group (25.1 months vs.23.5 months vs 25.6 months vs.25.8 months) (P> 0.05). The incidence of radiation cystitis in the experimental group was higher than that in the control group (P <0.05). There was no significant difference in the incidence of gastrointestinal reactions, bone marrow suppression and radiation proctitis between the two groups (P> 0.05). Conclusion Metformin may enhance the chemoradiation of radiotherapy and chemotherapy in advanced cervical cancer patients with T2DM.